Search the Newsreel

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung …

Cullinan, Taiho's Zipalertinib - Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up

(RTTNews) - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (CGEM) announced that the Phase 3 REZILIENT3 trial, evaluating the combination of zipalertinib and platinum-based chemotherapy in the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), met …

HC Wainwright Issues Pessimistic Outlook for CGEM Earnings

Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com

Cullinan Oncology (CGEM) stock has reached a new 52-week high of $19.43, reflecting a substantial increase of approximately 158% over the past year. The company's market capitalization now stands at $1.24 billion, driven by strong investor confidence and recent positive developments. These include favorable …

(CGEM) Movement as an Input in Quant Signal Sets

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to generate trading strategies. It highlights a strong near-term sentiment possibly leading to a long-term positive bias, with support being tested. The analysis provides specific entry, target, and stop-loss levels for position, momentum …

Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM

Renaissance Technologies LLC has reduced its stake in Cullinan Therapeutics (NASDAQ:CGEM) by 48.7% during the first quarter, selling 307,595 shares and retaining 324,111 shares valued at $4.6 million. Despite this sale, institutional investors collectively hold 86.31% of the company's stock, and analysts maintain a …

Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its immunology and oncology pipeline. The company reported promising clinical data for CLN-978 and velinotamig in autoimmune diseases, with Phase 2 studies anticipated to begin in early 2027. …

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history

This article provides a detailed overview of Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company focused on autoimmune diseases and cancer. It includes current stock price, historical data, financial metrics, analyst ratings, and a company profile highlighting its drug development pipeline. The company's stock …

Cullinan to begin potentially registrational acute myeloid leukemia study in Q3

Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially …

Cullinan Oncology earnings up next: Can pipeline justify cash burn?

Cullinan Therapeutics Inc. is set to report second-quarter earnings, with analysts expecting a wider loss per share. The pre-revenue biotech, with a $1.08 billion market cap, is advancing two late-stage oncology programs, CLN-049 and zipalertinib, which have garnered bullish Wall Street sentiment and significant …

Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen

Cullinan Therapeutics (CGEM) Expected to Release Quarterly Earnings on Thursday

Liquidity Mapping Around (CGEM) Price Events

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies key support and resistance levels, offering three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. …

For AML patients with limited options, Cullinan plans a new study

Cullinan Therapeutics received positive feedback from the FDA for its FLT3xCD3 T cell engager CLN-049 in acute myeloid leukemia (AML), paving the way for a potentially registrational Phase 2 study in Q3 2026. The study will focus on relapsed/refractory AML, an area with limited …

Why is Cullinan Therapeutics stock climbing today?

Cullinan Therapeutics (CGEM) stock rose in pre-open trading after receiving positive FDA feedback for CLN-049, a drug for relapsed/refractory acute myeloid leukemia. The company plans to initiate a potentially registrational Phase 2 study in Q3 2026, which investors view as an accelerated path to …

Why (CGEM) Price Action Is Critical for Tactical Trading

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, highlighting a mid-channel oscillation pattern and a significant 51.8:1 risk-reward setup. It outlines various trading strategies including position trading, momentum breakout, and risk hedging, based on AI-generated signals and multi-timeframe analysis. The report …